Alveogene
Founded 2022 · 4 employees on LinkedIn · 1 known investors
AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
Founders & leadership
DH
David HipkissinExecutive Chair
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- ALVEOGENE LIMITED
- Company number
- 14342459
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Sept 2022
- Registered office
- C/O Oxford Science Enterprises, 46 Woodstock Road, Oxford, OX2 6HT
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 6 Sept 2025 · next due 20 Sept 2026
Current officers · 5
- Eric Walter Frederick Wolfgang Alton — director, appointed 7 Sept 2022
- Claire Brown — director, appointed 24 Jul 2023
- David John Hipkiss — director, appointed 24 Jul 2023
- Alistair James Mcdermott — director, appointed 11 Jul 2025
- John Rice — director, appointed 24 Jul 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Alveogene do?
- AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
- Who are Alveogene's investors?
- Alveogene's investors include Oxford Science Enterprises.